Blog
Pearl IRB granted full reaccreditation by AAHRPP
Pearl IRB is proud to announce its recent reaccreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP). The Final Site Visit Report was reviewed by the AAHRPP Council on Accreditation during its December 2017...
2017 Pearl IRB holiday hours
Our office will be closed December 25th, 26th, 31st and also on January 1st for the holidays. There will not be a Pearl IRB board meeting on December 27th or January 3rd.. The week of January 8th, the normal IRB Board meeting schedule will resume. If you need to talk...
Only 5% of cancer patients participate in clinical trials
There are over 2,000 immunotherapy drugs currently in development. However, a meagre 5% of cancer patients partake in clinical trials, according to a PBS News Hour report. Consequently, America’s second leading cause of death, cancer, continues to claim...
Perspectives on the FDA – Gretchen Bowker will speak during IHIF Life Sciences Lunch
Gretchen Bowker, COO and Head of Quality of Pearl IRB, will share insights during an Indiana Health Industry Forum (IHIF) lunch event on Tuesday, December 19, 2017. The lunch event, "Perspectives on the FDA" is part of IHIF's recurring Life Sciences Lunch...
FDA, EMA recommend more efficient approach to drug development for rare pediatric diseases
The United States Food and Drug Administration (FDA) released a new draft guidance as part of its stated commitment to assist sponsors and expedite drug development for rare pediatric diseases, Outsourcing-Pharma.com reports. FDA collaborated with the...